Company Description
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
The company’s testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection.
It also offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment.
The company sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers.
The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Country | Belgium |
| Founded | 2003 |
| IPO Date | Nov 4, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 312 |
| CEO | Michael McGarrity |
Contact Details
Address: CAP Business Center, Rue d’Abhooz 31 Herstal, 4040 Belgium | |
| Phone | 32 1 259 56 44 |
| Website | mdxhealth.com |
Stock Details
| Ticker Symbol | MDXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.46 |
| CIK Code | 0001872529 |
| CUSIP Number | 58286E102 |
| ISIN Number | US58286E1029 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Michael K. McGarrity | Chief Executive Officer and Executive Director |
| Ron Kalfus CPA | Chief Financial Officer |
| Joseph Sollee J.D., LLM | Executive Vice President of Corporate Development and General Counsel |
| John A. Bellano | Chief Commercial Officer |
| Miriam Reyes | Executive Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2025 | 6-K | Report of foreign issuer |
| May 2, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 21, 2025 | SCHEDULE 13G/A | Filing |
| Mar 7, 2025 | 6-K | Report of foreign issuer |
| Feb 26, 2025 | 6-K | Report of foreign issuer |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 6-K | Report of foreign issuer |